Certara, Inc. (NASDAQ:CERT – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 4,400,000 shares, a decrease of 15.7% from the May 31st total of 5,220,000 shares. Based on an average daily volume of 576,300 shares, the days-to-cover ratio is currently 7.6 days. Approximately 4.0% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the stock. KeyCorp raised shares of Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 price target on the stock in a report on Wednesday, April 10th. JMP Securities initiated coverage on Certara in a research report on Thursday, April 4th. They set a “market perform” rating on the stock. Finally, Barclays lowered their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.81.
Read Our Latest Analysis on Certara
Insider Buying and Selling
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Pineridge Advisors LLC purchased a new stake in Certara in the fourth quarter valued at $28,000. Global Retirement Partners LLC lifted its holdings in shares of Certara by 5,306.3% in the 1st quarter. Global Retirement Partners LLC now owns 1,730 shares of the company’s stock valued at $31,000 after buying an additional 1,698 shares during the period. YHB Investment Advisors Inc. purchased a new stake in shares of Certara in the first quarter worth about $47,000. Natixis Advisors L.P. grew its holdings in Certara by 13.4% during the third quarter. Natixis Advisors L.P. now owns 15,136 shares of the company’s stock worth $220,000 after acquiring an additional 1,791 shares during the period. Finally, Pacer Advisors Inc. raised its position in Certara by 1,704.0% during the fourth quarter. Pacer Advisors Inc. now owns 12,754 shares of the company’s stock valued at $224,000 after acquiring an additional 12,047 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.
Certara Stock Performance
Certara stock traded down $0.21 during trading hours on Monday, hitting $13.64. 665,945 shares of the stock traded hands, compared to its average volume of 567,172. The firm’s 50 day moving average price is $15.98 and its 200-day moving average price is $16.86. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -34.97, a P/E/G ratio of 4.65 and a beta of 1.53. Certara has a 1 year low of $11.81 and a 1 year high of $19.87.
Certara (NASDAQ:CERT – Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm had revenue of $96.65 million during the quarter, compared to analysts’ expectations of $94.48 million. As a group, equities analysts expect that Certara will post 0.29 EPS for the current fiscal year.
Certara Company Profile
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
- Five stocks we like better than Certara
- What Does a Stock Split Mean?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Healthcare Dividend Stocks to Buy
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Overbought Stocks Explained: Should You Trade Them?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.